|
MRPS35 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.26779999959959E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.80259999985155E-07 |
| Normal-vs-Stage2 |
3.913400E-01 |
| Normal-vs-Stage3 |
9.56199999957441E-07 |
| Normal-vs-Stage4 |
4.89579999873868E-08 |
| Stage1-vs-Stage2 |
6.583400E-03 |
| Stage1-vs-Stage3 |
6.799800E-01 |
| Stage1-vs-Stage4 |
1.633010E-01 |
| Stage2-vs-Stage3 |
5.583900E-03 |
| Stage2-vs-Stage4 |
8.605400E-04 |
| Stage3-vs-Stage4 |
3.234200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.30120000014267E-08 |
| Normal-vs-AfricanAmerican |
3.964700E-04 |
| Normal-vs-Asian |
1.00680000003628E-06 |
| Caucasian-vs-AfricanAmerican |
9.659800E-01 |
| Caucasian-vs-Asian |
6.195000E-01 |
| AfricanAmerican-vs-Asian |
6.779400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.57910000001083E-06 |
| Normal-vs-Female |
1.70919999997743E-06 |
| Male-vs-Female |
3.677200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.55139999963505E-07 |
| Normal-vs-Age(41-60Yrs) |
1.35810000001513E-06 |
| Normal-vs-Age(61-80Yrs) |
1.750440E-04 |
| Normal-vs-Age(81-100Yrs) |
2.041600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.112600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.670410E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.081800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.613400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.579800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.726600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.857200E-01 |
| Classical-VS-Follicular |
2.004400E-02 |
| Classical-VS-Other |
3.446800E-01 |
| Classical-VS-Normal |
3.66169999876931E-08 |
| Tall-VS-Follicular |
5.417600E-02 |
| Tall-VS-Other |
3.727600E-01 |
| Tall-VS-Normal |
1.180560E-04 |
| Follicular-VS-Other |
1.785820E-01 |
| Follicular-VS-Normal |
4.294400E-02 |
| Other-VS-Normal |
3.297200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.73069999999109E-05 |
| Normal-vs-N1 |
5.11000020075869E-10 |
| N0-vs-N1 |
1.961960E-03 |
|
|
